Previous 10 | Next 10 |
ANI Pharmaceuticals (NASDAQ:ANIP) said it got U.S. Food and Drug Administration approval for its generic drug application for fludrocortisone acetate tablets. The Baudette, Minn.-based company's shares gained 6.1% to $32.39 in aftermarket trading on Wednesday. The approval was for A...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application (ANDA) for Fludrocortisone Acetate Tablets US...
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at two upcoming conferences as follows: The webcasts will be accessible via the Company’s websi...
ANI Pharmaceuticals, Inc. (ANIP) Q1 2022 Earnings Conference Call May 10, 2022 8:30 a.m. ET Company Participants Lisa Wilson - Investor Relations Nikhil Lalwani - President and Chief Executive Officer Steve Carey - Chief Financial Officer Chris Mutz - Head of Rare Disease Conference Call Part...
ANI Pharmaceuticals press release (NASDAQ:ANIP): Q1 Non-GAAP EPS of -$0.12 misses by $0.21. Revenue of $64.48M (+18.3% Y/Y) misses by $0.55M. Provides Purified Cortrophin® Gel 2022 Net Revenue guidance of $35 million to $40 million, Total Company Net Revenue guidance of $295 million...
-- First quarter net revenues of $64.5 million, net loss of $(20.1) million and diluted GAAP loss per share of $(1.27) -- -- First quarter adjusted non-GAAP EBITDA of $4.3 million and adjusted non-GAAP diluted loss per share of $(0.12) -- -- Provides Purified Cortrophi...
ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is $0.09 (-91.3% Y/Y) and the consensus Revenue Estimate is $65.03M (+19.3% Y/Y). Over the last 2 years, ANIP has beaten EPS estimates 63% of the...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2022 financial results on Tuesday, May 10, 2022. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey,...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Misoprostol Tablets, 100 mcg and 200 mcg. ANI’s Misoprostol Tablets are the generic version of the Reference Listed Drug (RLD) Cytotec ® . The ...
Shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) traded today at $86.44, eclipsing its 52-week high. Approximately 12.2 million shares have changed hands today, as compared to an average 30-day volume of 187,000 shares. ANI Pharmaceuticals Inc. (NASDAQ:ANIP) is currently priced 2.0% abov...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....